Picture of Biolife Sciences logo

BLFE Biolife Sciences Income Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

Annual income statement for Biolife Sciences, fiscal year end - November 30th, USD millions except per share, conversion factor applied.

C2006
November 30th
2007
November 30th
2010
November 30th
2011
November 30th
2012
November 30th
Period Length:12 M12 M12 M12 M12 M
Source:10KSB10KSBARSARS10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue6.418.6000
Cost of Revenue
Gross Profit1.081.57000
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses5.879.27-1.790.2930.124
Operating Profit0.543-0.6691.79-0.293-0.124
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes0.543-0.6691.72-0.293-0.202
Provision for Income Taxes
Net Income After Taxes0.543-0.6691.72-0.293-0.202
Net Income Before Extraordinary Items
Net Income0.543-0.6691.72-0.293-0.202
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income0.543-0.6691.72-0.293-0.202
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS308-202-1.26-0.63-0.937
Dividends per Share

Or unlock with your email

Or unlock with your email